Treatment Outcome of non-Hodgkin Lymphoma Patients : Maharaj Nakhon Si Thammarat Hospital experience
Keywords:
non-Hodgkin Lymphoma, survival, LDH, febrile neutropeniaAbstract
Background: Malignant lymphoma is one of the most common hematologic malignancy. Treatment outcome of the malignant lymphoma is good response. Objective: To study non-Hodgkin lymphoma patients, treatment outcome in Maharaj Nakhon Si Thammarat Hospital. METHODS: This is a retrospective study. The patients older than 15 years who had been diagnosed with non-Hodgkin Lymphoma (NHL) and had been enrolled from 1
October 2007 to 30 September 2011. The data recorded in medical records were reviewed of age, gender, type of cancer, imaging examination, staging, type of chemotherapy. RESULTS: There were 82 patients in this study. Mean age of the patients was 56 years old. The male/female ratio was 1.56:1 Patients were presented in stage I, II- 57 cases and stage III,IV-25 cases. The histologic types included were diffuse large B cell lymphoma-63 cases, peripheral
T-cell lymphoma-5 case, marginal Zone lymphoma-3 cases, Follicular lymphoma-2 cases, Extranodal NK/T-cell lymphoma-2 cases, Subcutaneous T-cell lymphoma-2 cases, Chronic Lymphocytic leukemia/Small lymphocytic lymphoma-1 case, Anaplastic large cell lymphoma-1case and unspecific type-2 cases. 72 patients were treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen and 3 patients were treated with R-CHOP regimens. In this study 57.30% achieved Complete remission (CR) and 4.80% achieved Partial response (PR) and Stable response (SD) response 3 year overall survival of this study are 61.50%.A comparative study between the group with normal LDH level compared to the higher LDH level found that 3 years overall survival higher than the higher group with statistic significant. The incidence of febrile neutropenia (FN) was 19.50% (16/82). Low serum albumin (p=0.005) was highly significantly associated with a risk of FN. CONCLUSION: Treatment of non-Hodgkin’s lymphoma has a similar response rate to other study. In patient with normal level of LDH patients showed overall survival is better than the high level of LDH. The serum albumin level was found that to be statistically significant predictor of febrile neutropenia
References
Prayoonwiwat W, SriChaikul T. Clinicopathological analysis of malignant lymphoma 100 case from Phramongkutklao Hospital. Intern Med 1986;2:193-200.
Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25:1916–23.
Intragumtornchai T, Bunworasate U, Wudhikarn K, et al. Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. Hematological Oncology. 2018;36:28–36.
Intragumtornchai T, Sutcharitchan P, ahasandhana S, et al. Prognostic factors of Thai Patients with aggressive NHL abstract present ใน International Society of Hematology Congress Brisban, Australia. 1995.
ถนอมศรี ศรีชัยกุล, วิชัย ประยูรวิวัฒน์, วิเชียร มงคลศรีตระกูล, วิชัย อติชาตการ, บุญสม ชัยมงคล, อนงค์ เพียรกิจกรรม, และคณะ.การรักษาผู้ป่วย NHL:ศึกษาเปรียบเทียบการใช้ CHOP และ CEOPจาก 5 สถาบันระหว่างปี ค.ศ. 1986-1988. วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต 2537; 2:93-100.
อุดมลักษณ์ เจนพาณิชย์. มะเร็งต่อมนํ้าเหลืองในโรงพยาบาลพุทธชินราชปี 2549-2550. พุทธชินราชเวชสาร 2551;25:464-471.
ธราธร ธรรมประสิทธิ์, อานุภาพ เลขากุล. CVP VS CHOP in intermediate and High Grade NHL:วารสารโลหิตวิยาและเวชศาสตร์บริการโลหิต 2534; 1(2) : 153-63
Grogan L, Corbally N, Dervan PA, Byrne A, Carney DN. Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin’s lymphoma treated with standard-dose adriamycin-based regimens. Ann Oncol 1994;5 Suppl 2:47-51.
Feugier P, Van Hoof A, Sebban C, et al. Long-Term Results of the R-CHOP Study in theTreatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-26.
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010; 116:2040-5
Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-Bcell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 5:379-91.
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
Ugroseno, Muhamad Ali, Boediwarsono. Lactate dehydrogenase level and the response of non Hodgkin lymphoma pateintstochemotherapy cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP). Folia Medica Indonesiana. 2008;44: 184-187.
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model of aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987-94.
Magdy William B, Rao Bongu N, Bast M. The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter 2013;35(3):189-91.
Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2000;37:351-60.
Saleem L, Anjum Zahid N, IS Serum Albumin an Indepentdent Predictor of post Chemotherapy Febrile neutropenia? Pak Armed Forces Med J 2017; 67(5): 768-74.
Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402–9.
จุฑารัตน์ สุธีโสภณ. การศึกษาปัจจัยเสริมการเกิดภาวะโลหิตขาวตํ่ารุนแรงในผู้ป่วยมะเร็งต่อมนํ้าเหลืองที่ได้รับยาเคมีบำบัด (วิทยานิพนธ์มหาบัณฑิต). ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ กรุงเทพมหานคร:จุฬาลงกรณ์มหาวิทยาลัย; 2540.
